Search
forLearn
5 / 801 resultslearn copper tripeptide-1
learn Tripeptide-1
learn oligopeptide-71
learn octapeptide-2
Research
5 / 567 results
research Role of plasminogen activator inhibitor type 1 (PAI-1) in PCOS patient
People with PCOS have higher levels of PAI-1, which may increase their risk of heart disease and fertility issues.
research Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women
Birth control pills change the activity of certain inflammation and blood clotting genes in women with PCOS.
research Deletion of adipocyte Sine Oculis Homeobox Homolog 1 prevents lipolysis and attenuates skin fibrosis
Removing SIX1 in fat cells reduces skin fibrosis.
research Wound healing in development
Wounds heal without scarring in early development but later result in scars, and studying Wnt signaling could help control scarring.
research Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome
Women with PCOS have higher levels of certain blood clotting factors, suggesting a greater risk of cardiovascular issues.
Community Join
5 / 21 resultscommunity How ET-02 Works. Also no proof that it's better than Minoxidil. At least for now.
ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
community Insane MTF recovery 18 months blocking androgens
Hair loss recovery using estrogen and anti-androgen treatment for 18 months showed significant improvement. However, results vary and alternative treatments like RU58841 and Dutasteride may work without systemic feminization.
community 21F AGA - 4 month hair growth progress (Minoxidil 5%, finasteride 1mg, theradome LLLT, viviscal vitamins, PRP twice)
A 21-year-old female shared her 4-month hair growth progress using Minoxidil 5%, finasteride 1mg, Theradome LLLT, Viviscal vitamins, and PRP treatments twice. Commenters praised her progress and discussed other treatments like microneedling, but she noted her dermatologist advised against it due to potential scalp damage.